Natus Medical Inc. (BABY) Shares Down 2.4%
Shares of Natus Medical Inc. (NASDAQ:BABY) traded down 2.4% during trading on Wednesday . The company traded as low as $38.99 and last traded at $39.33, with a volume of 475,506 shares traded. The stock had previously closed at $40.30.
A number of analysts recently commented on the stock. Roth Capital reiterated a “buy” rating on shares of Natus Medical in a research note on Thursday, April 21st. Zacks Investment Research upgraded shares of Natus Medical from a “hold” rating to a “buy” rating and set a $44.00 price objective for the company in a research note on Thursday, July 7th. Finally, Raymond James Financial Inc. cut shares of Natus Medical from an “outperform” rating to a “market perform” rating in a research note on Tuesday, April 5th.
The company’s 50 day moving average is $37.11 and its 200 day moving average is $35.70. The firm has a market capitalization of $1.29 billion and a price-to-earnings ratio of 34.62.
Natus Medical (NASDAQ:BABY) last released its quarterly earnings results on Wednesday, July 20th. The company reported $0.39 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.36 by $0.03. The firm had revenue of $96 million for the quarter, compared to analyst estimates of $92.71 million. On average, equities analysts predict that Natus Medical Inc. will post $1.66 earnings per share for the current year.
In other news, Director Robert A. Gunst sold 5,000 shares of Natus Medical stock in a transaction on Tuesday, April 26th. The stock was sold at an average price of $34.61, for a total transaction of $173,050.00. Following the completion of the transaction, the director now owns 55,000 shares of the company’s stock, valued at approximately $1,903,550. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, VP Kenneth M. Traverso sold 7,459 shares of Natus Medical stock in a transaction on Friday, April 22nd. The stock was sold at an average price of $33.56, for a total value of $250,324.04. Following the transaction, the vice president now directly owns 112,119 shares of the company’s stock, valued at approximately $3,762,713.64. The disclosure for this sale can be found here.
Several hedge funds and institutional investors have recently added to or reduced their stakes in the company. Hodges Capital Management Inc. increased its position in Natus Medical by 2.2% in the fourth quarter. Hodges Capital Management Inc. now owns 818,194 shares of the company’s stock valued at $39,314,000 after buying an additional 17,821 shares during the period. Wells Fargo & Company MN increased its position in Natus Medical by 533.8% in the fourth quarter. Wells Fargo & Company MN now owns 406,530 shares of the company’s stock valued at $19,534,000 after buying an additional 342,390 shares during the period. Morgan Stanley increased its position in Natus Medical by 108.0% in the fourth quarter. Morgan Stanley now owns 242,583 shares of the company’s stock valued at $11,656,000 after buying an additional 125,964 shares during the period. Principal Financial Group Inc. boosted its stake in Natus Medical by 6.5% in the fourth quarter. Principal Financial Group Inc. now owns 222,296 shares of the company’s stock worth $10,682,000 after buying an additional 13,504 shares in the last quarter. Finally, Advisors Asset Management Inc. boosted its stake in Natus Medical by 20.7% in the fourth quarter. Advisors Asset Management Inc. now owns 189,045 shares of the company’s stock worth $9,084,000 after buying an additional 32,424 shares in the last quarter.
Natus Medical Incorporated is a provider of newborn care and neurology healthcare products and services used for the screening, diagnosis, detection, treatment, monitoring and tracking of common medical ailments in newborn care, hearing impairment, neurological dysfunction, epilepsy, sleep disorders, neuromuscular diseases and balance and mobility disorders.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.